[1]方庆亮,王 蕾,刘 雪,等.再造丸联合放疗治疗晚期非小细胞肺癌脑转移临床观察[J].陕西中医,2024,(12):1625-1629.[doi:DOI:10.3969/j.issn.1000-7369.2024.12.008]
　FANG Qingliang,WANG Lei,LIU Xue,et al.Clinical study on brain metastases of late stage non-small cell lung cancer treated with Zaizao pill combined with radiotherapy[J].,2024,(12):1625-1629.[doi:DOI:10.3969/j.issn.1000-7369.2024.12.008]
点击复制

再造丸联合放疗治疗晚期非小细胞肺癌脑转移临床观察
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2024年12期
页码:
1625-1629
栏目:
临床研究
出版日期:
2024-12-05

文章信息/Info

Title:
Clinical study on brain metastases of late stage non-small cell lung cancer treated with Zaizao pill combined with radiotherapy
作者:
方庆亮; 王 蕾; 刘 雪; 顾煜恺; 顾香莲; 鹿振辉
(上海中医药大学附属龙华医院,上海 200032)
Author(s):
FANG Qingliang; WANG Lei; LIU Xue; GU Yukai; GU Xianglian; LU Zhenhui
(Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 200032,China)
关键词:
非小细胞肺癌;  再造丸;  放疗;  脑转移;  生存周期;  肿瘤因子;  生活质量
Keywords:
Non-small cell lung cancer;  Zaizao pill;  Radiotherapy;  Brain metastases;  Life cycle;  Tumor factor;  Quality of life
分类号:
R 734.2
DOI:
DOI:10.3969/j.issn.1000-7369.2024.12.008
文献标志码:
A
摘要:
目的:探讨再造丸联合放疗治疗晚期非小细胞肺癌脑转移的临床疗效。方法:选择晚期非小细胞肺癌脑转移患者78例,采取简单化分组方法分为两组,各39例,对照组给予放疗,观察组在其基础上给予再造丸治疗,观察两组患者治疗前后生存周期[中位无进展生存期(PFS)、中位总生存时间(OS)]、中医证候评分、中医证候疗效评价、血清肿瘤因子[血清癌胚抗原(CEA)、细胞角蛋白19片段抗原21-1(CYFRA21-1)、糖类抗原125(CA125)]、肺癌患者生活质量量表(EORTC QLQ-LC43)评分及不良反应。结果:治疗后两组中医证候评分、血清肿瘤因子水平较治疗前降低,且观察组低于对照组(均P<0.05)。治疗后观察组中医证候总有效率为89.74%显著高于对照组的71.79%(P<0.05)。治疗后两组情感功能、社会功能、生理功能、角色功能、认知功能、总健康状况评分较治疗前升高,且观察组高于对照组(均P<0.05)。观察组生存周期长于对照组(P<0.05)。治疗期间两组不良反应总发生率比较差异无统计学意义(P>0.05)。结论:再造丸联合放疗可有效提高晚期非小细胞肺癌脑转移患者生存周期及生活质量。
Abstract:
Objective:To observe the Zaizao pill combined with chemotherapy in the treat of NSCLC with brain metastases.Methods:A total of 78 patients with NSCLC with brain metastases were divided into two group.The contrast group was given radiotherapy,and the observe group was given Zaizao pill on the basis of the contrast group.The survival cycle [median progression-free survival(PFS),median overall survival(OS)],TCM syndrome score,TCM syndrome efficacy evaluation,serum tumor factors [serum carcinoembryonic antigen(CEA),cytokeratin 19 fragment(CYFRA21-1),carbohydrate antigen 125(CA125)],EORTC QLQ-LC43 score and adverse reactions of the two groups before and after treatment were observed.Results:After treatment,TCM syndrome score and serum tumor factor levels of the observe group were lower than before treatment and contrast group(all P<0.05).Total effective rate of the TCM syndromes in observe group was higher than control group(P<0.05).After treatment,the EORTC QLQ-LC43 scores in observe group were higher than before treatment and contrast group(all P<0.05),and survival cycle in observe group higher than contrast group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups during treatment(P>0.05).Conclusion:Zaizao pill combined with chemotherapy can effectively improve the survival cycle and quality of life of advanced non-small cell lung cancer patients with brain metastases.

参考文献/References:

[1] HENDRIKS L E,KERR K M,MENIS J,et al.Non-oncogene-addicted metastatic non-small-cell lung cancer:ESMO clinical practice guideline for diagnosis,treatment and follow-up[J].Ann Oncol,2023,34(4):358-376.
[2] CHEN K,YANG F,SHEN H,et al.Individualized tumor-informed circulating tumor DNA analysis for postoperative monitoring of non-small cell lung cancer[J].Cancer Cell,2023,41(10):1749-1762.
[3] ETTINGER D S,WOOD D E,AISNER D L,et al.NCCN guidelines insights:Non-small cell lung cancer,version 2.2023[J].J Natl Compr Canc Netw,2023,21(4):340-350.
[4] CHU X,NIU L,XIAO G,et al.The long-term and short-term efficacy of immunotherapy in non-small cell lung cancer patients with brain metastases:A systematic review and meta-analysis[J].Front Immunol,2022,13:875488.
[5] PAN Y,ZHANG J T,GAO X,et al.Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients[J].Cancer Cell,2023,41(10):1763-1773.
[6] KROL K,MAZUR A,STACHYRA-STRAWA P,et al.Non-small cell lung cancer treatment with molecularly targeted therapy and concurrent radiotherapy-a review[J].Int J Mol Sci,2023,24(6):5858.
[7] 阚书慧,张丹.温阳益髓方联合直接灸四花穴对非小细胞肺癌化疗所致骨髓抑制患者免疫功能及肿瘤相关抗原的影响[J].陕西中医,2024,45(2):200-203.
[8] 于盼,刘洋,郑彩霞,等.益气养阴方联合化疗、甲磺酸奥希替尼片治疗非小细胞肺癌脑转移的临床疗效观察[J].河北中医,2021,43(1):87-91.
[9] 杨松,徐力.健脾除湿化痰方治疗气虚痰湿型非小细胞肺癌脑转移的效果及对患者生活质量的影响[J].中国医药导报,2020,17(23):138-141,166.
[10] 王军徽,肖萌,马功贤,等.非小细胞肺癌中医药治疗研究进展[J].陕西中医,2023,44(11):1663-1665.
[11] 周茜雅,宁娜,童庆,等.华佗再造丸对高脂血症小鼠的作用研究[J].中药药理与临床,2021,37(6):119-124.
[12] 中国医师协会肿瘤医师分会,中国医疗保健国际交流促进会肿瘤内科分会.肺癌脑转移中国治疗指南(2021年版)[J].中华肿瘤杂志,2021,43(3):269-281.
[13] 林洪生.恶性肿瘤中医诊疗指南[M].北京:人民卫生出版社,2014:200-204.
[14] 国家食品药品监督管理总局.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:216-221.
[15] ZHANG L,SU Y,HUA Y,et al.Validation of EORTC QLQ-LC43 for Chinese patients with lung cancer[J].Lung Cancer,2014,85(1):94-98.
[16] 刘芳芳,姜怡,蔡雨晴,等.基于“肺脑相系”理论探讨肺癌脑转移的中医发病机制[J].上海中医药杂志,2023,57(7):1-4.
[17] 周家香,吴春芝,冯芳,等.康莱特静脉注射联合顺铂灌注对晚期非小细胞肺癌患者免疫功能和肿瘤标志物的影响[J].陕西医学杂志,2024,53(6):818-822.
[18] 胡建伟,袁香坤,张永侠,等.不同消融方式联合靶向治疗对非小细胞肺癌的疗效及对患者血清指标的影响[J].陕西医学杂志,2024,53(4):527-530.
[19] 徐佳宁.中药治疗对肺癌脑转移患者预后的影响[D].沈阳:辽宁中医药大学,2022.
[20] 司亚克,吕梦果,陈东东.非小细胞肺癌脑转移瘤患者血清CY21-1、SCC-Ag水平变化及其检测价值分析[J].实用癌症杂志,2023,38(3):427-430.
[21] 苏晓宁,郑建清,陈樱.SF-36量表和EORTC QLQ-LC43量表在肺癌患者生活质量测定中的应用效果[J].中国卫生标准管理,2023,14(9):114-120.
[22] 雷靓.系统评价中药十全大补汤防治化疗所致骨髓抑制疗效及临床研究[D].济南:山东中医药大学,2022.
[23] 郭刚,许建华,韩建宏,等.十全大补汤抑制Lewis肺癌原发瘤切除后转移瘤的研究[J].中国实验方剂学杂志,2012,18(10):279-284.
[24] 尹硕淼,高志凌,聂卫群.虫类药在肺系疾病中的应用探析[J].陕西中医药大学学报,2021,44(5):59-62.
[25] 何伟.活血化瘀中药重塑肿瘤微环境[J].中医学报,2024,39(6):1188-1194.
[26] 陈纯辉,孙学刚,魏素芬,等.肿瘤微环境血瘀病机探讨[J].中西医结合研究,2023,15(3):195-197,201.

相似文献/References:

[1]刘月芬,刘小红,于明军,等.清金化痰汤治疗非小细胞肺癌临床研究[J].陕西中医,2019,(2):229.
　LIU Yuefen,LIU Xiaohong,YU Mingjun,et al.Clinical observation of nonsmall cell lung cancer patients treated with Qingjin Huatan decoction[J].,2019,(12):229.
[2]陈姣红,古红莉,员建中,等.参术扶正抗癌汤联合化疗及三维适形放疗对晚期非小细胞肺癌患者 血清T细胞亚群水平及生存质量的影响*[J].陕西中医,2019,(5):564.
[3]张栓宝,严宁娟△,张燕平.复方斑蝥胶囊对非小细胞肺癌患者围术期血清炎症因子及免疫功能的影响[J].陕西中医,2019,(7):890.
[4]任宝中,李 媛△.益气化瘀方配合化疗治疗晚期非小细胞肺癌临床研究*[J].陕西中医,2019,(8):1036.
　REN Baozhong,LI Yuan..Application effect of TP chemotherapy Plus Yiqi Huayu decoction in advanced Non-small cell lung cancer patients[J].,2019,(12):1036.
[5]任东峰,孙国芳△.六君祛痰解毒汤联合化疗治疗非小细胞肺癌疗效〖JZ〗及对患者血管内皮生长因子的影响[J].陕西中医,2020,(1):63.
[6]刘 婷,李 洋,石志红.灯盏花素对非小细胞肺癌A549细胞的作用及机制研究[J].陕西中医,2021,(10):1363.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.009]
　LIU Ting,LI Yang,SHI Zhihong.Effects of breviscapine on proliferation and apoptosis of non-small cell lung cancer A549 cells[J].,2021,(12):1363.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.009]
[7]肖 凌,王 洋,钱建新,等.生脉饮合沙参麦冬汤联合西药治疗晚期非小细胞肺癌疗效研究[J].陕西中医,2021,(12):1696.[doi:DOI:10.3969/j.issn.1000-7369.2020.12.010]
[8]陈香梅,刘太锋,杨 明,等.复方苦参注射液联合化疗治疗非小细胞肺癌疗效研究[J].陕西中医,2021,(12):1700.[doi:DOI:10.3969/j.issn.1000-7369.2020.12.011]
[9]王理槐,孙银辉,张领兄,等.基于Wnt/β-catenin信号通路探讨血府逐瘀汤在非小细胞肺癌EGFR-TKI获得性耐药中的作用[J].陕西中医,2022,(4):427.[doi:DOI:10.3969/j.issn.1000-7369.2022.04.004]
　WANG Lihuai,SUN Yinhui,ZHANG Lingxiong,et al.Efficacy of Xuefu Zhuyu decoction in EGFR-TKI-Acquired resistance of non-small cell lung carcinoma based on the Wnt/β-catenin signaling pathway[J].,2022,(12):427.[doi:DOI:10.3969/j.issn.1000-7369.2022.04.004]
[10]屈 直,王 芬,李志明,等.二陈汤对Lewis肺癌移植瘤生长及Hedgehog通路蛋白表达的影响[J].陕西中医,2022,(5):555.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.003]
　QU Zhi,WANG Fen,LI Zhiming,et al.Effect of Erchen decoction on the expression of Hedgehog pathway protein in Lewis lung cancer transplanted tumor[J].,2022,(12):555.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.003]

备注/Memo

备注/Memo:
基金项目:上海市科技计划项目(21Y11922400); “龙医科技创新培育计划”临床医学引导项目(YD202204)
更新日期/Last Update: 2024-12-05